Teva Could Market Generic Lipitor by Month’s End, Calcalist Says

Teva Pharmaceutical Industries Ltd. (TEVA) could begin marketing a generic version of Lipitor by the end of the month through a partnership with India’s Ranbaxy Laboratories Ltd. (RBXY), Calcalist reported today, without saying how it obtained the information..

A message left on the answering machine of a Teva spokesman before office hours was not immediately answered.

Click here for web link

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Calev Ben-David at cbendavid@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.